Vistagen Therapeutics, Inc. (VTGN) stock
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.20+0.01 (+6.12%)
Close on Nov 18, 2026Market cap $8.85MP/E –Yield –
Vistagen Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Vistagen Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $2.50M. For fiscal 2026 it was $1.27M, up 161.1% from the year before. Over ten years it grew 20.3% a year on average. The highest annual figure on record is $2.07M in fiscal 2011.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $1.27M | +161.1% |
| FY2025 | Mar 31, 2025 | $486.00K | -54.3% |
| FY2024 | Mar 31, 2024 | $1.06M | – |
| FY2023 | Mar 31, 2023 | -$227.00K | -120.5% |
| FY2022 | Mar 31, 2022 | $1.11M | +1.8% |
| FY2021 | Mar 31, 2021 | $1.09M | – |
| FY2020 | Mar 31, 2020 | $0 | – |
| FY2018 | Mar 31, 2018 | $0 | -100.0% |
| FY2017 | Mar 31, 2017 | $1.25M | – |
| FY2016 | Mar 31, 2016 | $0 | -100.0% |
| FY2013 | Mar 31, 2013 | $200.40K | -85.1% |
| FY2012 | Mar 31, 2012 | $1.34M | -35.2% |
| FY2011 | Mar 31, 2011 | $2.07M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $1.48M | +504.9% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $465.00K | +98.7% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $303.00K | +65.6% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $258.00K | +207.1% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $244.00K | +23.9% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $234.00K | -43.1% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $183.00K | -34.2% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $84.00K | -52.5% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $197.00K | +11.9% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $411.00K | +128.3% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $278.00K | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $177.00K | -42.9% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $176.00K | +351.3% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $180.00K | -49.7% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$893.00K | -349.4% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $310.10K | -12.4% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $39.00K | -91.2% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $358.00K | +14.2% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $358.00K | +7.2% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $354.00K | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $442.00K | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $313.60K | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $334.00K | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $0 | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $0 | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $0 | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $0 | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $0 | -100.0% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $0 | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $0 | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $0 | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $1.25M | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $0 | – |
See a number that looks wrong?